Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Impact of obesity on breast cancer recurrence and minimal residual disease.

Ecker BL, Lee JY, Sterner CJ, Solomon AC, Pant DK, Shen F, Peraza J, Vaught L, Mahendra S, Belka GK, Pan TC, Schmitz KH, Chodosh LA.

Breast Cancer Res. 2019 Mar 13;21(1):41. doi: 10.1186/s13058-018-1087-7.

2.

Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition.

Gattelli A, García Solá ME, Roloff TC, Cardiff RD, Kordon EC, Chodosh LA, Hynes NE.

Oncogene. 2018 Jul;37(29):4046-4054. doi: 10.1038/s41388-018-0235-y. Epub 2018 Apr 26.

PMID:
29695833
3.

WNT-Mediated Regulation of FOXO1 Constitutes a Critical Axis Maintaining Pubertal Mammary Stem Cell Homeostasis.

Sreekumar A, Toneff MJ, Toh E, Roarty K, Creighton CJ, Belka GK, Lee DK, Xu J, Chodosh LA, Richards JS, Rosen JM.

Dev Cell. 2017 Nov 20;43(4):436-448.e6. doi: 10.1016/j.devcel.2017.10.007. Epub 2017 Nov 2.

4.

The women in steady exercise research (WISER) survivor trial: The innovative transdisciplinary design of a randomized controlled trial of exercise and weight-loss interventions among breast cancer survivors with lymphedema.

Winkels RM, Sturgeon KM, Kallan MJ, Dean LT, Zhang Z, Evangelisti M, Brown JC, Sarwer DB, Troxel AB, Denlinger C, Laudermilk M, Fornash A, DeMichele A, Chodosh LA, Schmitz KH.

Contemp Clin Trials. 2017 Oct;61:63-72. doi: 10.1016/j.cct.2017.07.017. Epub 2017 Jul 21.

5.

Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.

Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.

Breast Cancer Res Treat. 2017 Aug;164(3):639-640. doi: 10.1007/s10549-017-4339-9. No abstract available.

PMID:
28653249
6.

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.

Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.

Breast Cancer Res Treat. 2017 Aug;164(3):627-638. doi: 10.1007/s10549-017-4257-x. Epub 2017 May 12. Erratum in: Breast Cancer Res Treat. 2017 Jun 26;:.

7.

Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer.

Oran AR, Adams CM, Zhang XY, Gennaro VJ, Pfeiffer HK, Mellert HS, Seidel HE, Mascioli K, Kaplan J, Gaballa MR, Shen C, Rigoutsos I, King MP, Cotney JL, Arnold JJ, Sharma SD, Martinez-Outschoorn UE, Vakoc CR, Chodosh LA, Thompson JE, Bradner JE, Cameron CE, Shadel GS, Eischen CM, McMahon SB.

Oncotarget. 2016 Nov 8;7(45):72395-72414. doi: 10.18632/oncotarget.11718.

8.

A novel approach for next-generation sequencing of circulating tumor cells.

Yee SS, Lieberman DB, Blanchard T, Rader J, Zhao J, Troxel AB, DeSloover D, Fox AJ, Daber RD, Kakrecha B, Sukhadia S, Belka GK, DeMichele AM, Chodosh LA, Morrissette JJ, Carpenter EL.

Mol Genet Genomic Med. 2016 Feb 28;4(4):395-406. doi: 10.1002/mgg3.210. eCollection 2016 Jul.

9.

The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.

Turpin J, Ling C, Crosby EJ, Hartman ZC, Simond AM, Chodosh LA, Rennhack JP, Andrechek ER, Ozcelik J, Hallett M, Mills GB, Cardiff RD, Gray JW, Griffith OL, Muller WJ.

Oncogene. 2016 Nov 24;35(47):6053-6064. doi: 10.1038/onc.2016.129. Epub 2016 May 9.

10.

"Braking" the Cycle of Resistance in Endocrine Therapy for Breast Cancer.

DeMichele A, Chodosh LA.

Clin Cancer Res. 2015 Nov 15;21(22):4999-5001. doi: 10.1158/1078-0432.CCR-15-1146. Epub 2015 Jul 22.

11.

Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy.

Abravanel DL, Belka GK, Pan TC, Pant DK, Collins MA, Sterner CJ, Chodosh LA.

J Clin Invest. 2015 Jun;125(6):2484-96. doi: 10.1172/JCI74883. Epub 2015 May 11.

12.

Tetracycline-regulated mouse models of cancer.

Yeh ES, Vernon-Grey A, Martin H, Chodosh LA.

Cold Spring Harb Protoc. 2014 Oct 1;2014(10):pdb.top069823. doi: 10.1101/pdb.top069823. Review.

PMID:
25275112
13.

Oncogene pathway activation in mammary tumors dictates FDG-PET uptake.

Alvarez JV, Belka GK, Pan TC, Chen CC, Blankemeyer E, Alavi A, Karp JS, Chodosh LA.

Cancer Res. 2014 Dec 15;74(24):7583-98. doi: 10.1158/0008-5472.CAN-14-1235. Epub 2014 Sep 19.

14.

Ceramide kinase promotes tumor cell survival and mammary tumor recurrence.

Payne AW, Pant DK, Pan TC, Chodosh LA.

Cancer Res. 2014 Nov 1;74(21):6352-63. doi: 10.1158/0008-5472.CAN-14-1292. Epub 2014 Aug 27.

15.

Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.

Lee JV, Carrer A, Shah S, Snyder NW, Wei S, Venneti S, Worth AJ, Yuan ZF, Lim HW, Liu S, Jackson E, Aiello NM, Haas NB, Rebbeck TR, Judkins A, Won KJ, Chodosh LA, Garcia BA, Stanger BZ, Feldman MD, Blair IA, Wellen KE.

Cell Metab. 2014 Aug 5;20(2):306-319. doi: 10.1016/j.cmet.2014.06.004. Epub 2014 Jul 3.

16.

SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling.

Feng Y, Pan TC, Pant DK, Chakrabarti KR, Alvarez JV, Ruth JR, Chodosh LA.

Cancer Discov. 2014 Jul;4(7):790-803. doi: 10.1158/2159-8290.CD-13-0548. Epub 2014 Apr 30.

17.

Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer.

Searleman AC, Iliuk AB, Collier TS, Chodosh LA, Tao WA, Bose R.

Electrophoresis. 2014 Dec;35(24):3463-9. doi: 10.1002/elps.201400022. Epub 2014 Jun 12.

18.

Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy.

Alvarez JV, Pan TC, Ruth J, Feng Y, Zhou A, Pant D, Grimley JS, Wandless TJ, Demichele A; I-SPY 1 TRIAL Investigators, Chodosh LA.

Cancer Cell. 2013 Jul 8;24(1):30-44. doi: 10.1016/j.ccr.2013.05.007. Epub 2013 Jun 13.

19.

PUMA and BIM are required for oncogene inactivation-induced apoptosis.

Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, Cheng EH.

Sci Signal. 2013 Mar 26;6(268):ra20. doi: 10.1126/scisignal.2003483.

20.

Hunk negatively regulates c-myc to promote Akt-mediated cell survival and mammary tumorigenesis induced by loss of Pten.

Yeh ES, Belka GK, Vernon AE, Chen CC, Jung JJ, Chodosh LA.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6103-8. doi: 10.1073/pnas.1217415110. Epub 2013 Mar 21.

21.

The 2011-2016 Transdisciplinary Research on Energetics and Cancer (TREC) initiative: rationale and design.

Patterson RE, Colditz GA, Hu FB, Schmitz KH, Ahima RS, Brownson RC, Carson KR, Chavarro JE, Chodosh LA, Gehlert S, Gill J, Glanz K, Haire-Joshu D, Herbst KL, Hoehner CM, Hovmand PS, Irwin ML, Jacobs LA, James AS, Jones LW, Kerr J, Kibel AS, King IB, Ligibel JA, Meyerhardt JA, Natarajan L, Neuhouser ML, Olefsky JM, Proctor EK, Redline S, Rock CL, Rosner B, Sarwer DB, Schwartz JS, Sears DD, Sesso HD, Stampfer MJ, Subramanian SV, Taveras EM, Tchou J, Thompson B, Troxel AB, Wessling-Resnick M, Wolin KY, Thornquist MD.

Cancer Causes Control. 2013 Apr;24(4):695-704. doi: 10.1007/s10552-013-0150-z. Epub 2013 Feb 3.

22.

The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.

Thiel AT, Feng Z, Pant DK, Chodosh LA, Hua X.

Haematologica. 2013 Jun;98(6):918-27. doi: 10.3324/haematol.2012.074195. Epub 2013 Jan 24.

23.

Autocrine prolactin induced by the Pten-Akt pathway is required for lactation initiation and provides a direct link between the Akt and Stat5 pathways.

Chen CC, Stairs DB, Boxer RB, Belka GK, Horseman ND, Alvarez JV, Chodosh LA.

Genes Dev. 2012 Oct 1;26(19):2154-68. doi: 10.1101/gad.197343.112.

24.

miR-211 is a prosurvival microRNA that regulates chop expression in a PERK-dependent manner.

Chitnis NS, Pytel D, Bobrovnikova-Marjon E, Pant D, Zheng H, Maas NL, Frederick B, Kushner JA, Chodosh LA, Koumenis C, Fuchs SY, Diehl JA.

Mol Cell. 2012 Nov 9;48(3):353-64. doi: 10.1016/j.molcel.2012.08.025. Epub 2012 Sep 27.

25.

Lactate detection in inducible and orthotopic Her2/neu mammary gland tumours in mouse models.

Magnitsky S, Belka GK, Sterner C, Pickup S, Chodosh LA, Glickson JD.

NMR Biomed. 2013 Jan;26(1):35-42. doi: 10.1002/nbm.2816. Epub 2012 Jul 5.

26.

Preparation and characterization of L-[5-11C]-glutamine for metabolic imaging of tumors.

Qu W, Oya S, Lieberman BP, Ploessl K, Wang L, Wise DR, Divgi CR, Chodosh LA, Thompson CB, Kung HF.

J Nucl Med. 2012 Jan;53(1):98-105. doi: 10.2967/jnumed.111.093831. Epub 2011 Dec 15. Erratum in: J Nucl Med. 2012 Apr;53(4):646. Chodosh, Lewis P [corrected to Chodosh, Lewis A].

27.

PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.

Lieberman BP, Ploessl K, Wang L, Qu W, Zha Z, Wise DR, Chodosh LA, Belka G, Thompson CB, Kung HF.

J Nucl Med. 2011 Dec;52(12):1947-55. doi: 10.2967/jnumed.111.093815. Epub 2011 Nov 15.

28.

Breast cancer: current state and future promise.

Chodosh LA.

Breast Cancer Res. 2011;13(6):113. doi: 10.1186/bcr3045. Epub 2011 Nov 1. No abstract available.

29.

Inhibition of the single downstream target BAG1 activates the latent apoptotic potential of MYC.

Zhang XY, Pfeiffer HK, Mellert HS, Stanek TJ, Sussman RT, Kumari A, Yu D, Rigoutsos I, Thomas-Tikhonenko A, Seidel HE, Chodosh LA, Packham G, Baserga R, McMahon SB.

Mol Cell Biol. 2011 Dec;31(24):5037-45. doi: 10.1128/MCB.06297-11. Epub 2011 Oct 10.

30.

Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors.

Markosyan N, Chen EP, Ndong VN, Yao Y, Sterner CJ, Chodosh LA, Lawson JA, Fitzgerald GA, Smyth EM.

Carcinogenesis. 2011 Oct;32(10):1441-9. doi: 10.1093/carcin/bgr134. Epub 2011 Jul 18.

31.

Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer.

Yori JL, Seachrist DD, Johnson E, Lozada KL, Abdul-Karim FW, Chodosh LA, Schiemann WP, Keri RA.

Neoplasia. 2011 Jul;13(7):601-10.

32.

A targeted proteomics-based pipeline for verification of biomarkers in plasma.

Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, Kelly-Spratt KS, Krasnoselsky A, Gafken PR, Hogan JM, Jones LA, Wang P, Amon L, Chodosh LA, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG.

Nat Biotechnol. 2011 Jun 19;29(7):625-34. doi: 10.1038/nbt.1900.

33.

Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression.

Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, Nelson PS, Hanash SM, Kemp CJ.

Cancer Res. 2011 Aug 1;71(15):5090-100. doi: 10.1158/0008-5472.CAN-11-0568. Epub 2011 Jun 8.

34.

Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer.

Schoenherr RM, Kelly-Spratt KS, Lin C, Whiteaker JR, Liu T, Holzman T, Coleman I, Feng LC, Lorentzen TD, Krasnoselsky AL, Wang P, Liu Y, Gurley KE, Amon LM, Schepmoes AA, Moore RJ, Camp DG 2nd, Chodosh LA, Smith RD, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG.

Proteomics Clin Appl. 2011 Apr;5(3-4):179-88. doi: 10.1002/prca.201000037. Epub 2011 Feb 15.

35.

CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression.

Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C.

J Clin Invest. 2011 Mar;121(3):1064-74. doi: 10.1172/JCI44540.

36.

Hunk is required for HER2/neu-induced mammary tumorigenesis.

Yeh ES, Yang TW, Jung JJ, Gardner HP, Cardiff RD, Chodosh LA.

J Clin Invest. 2011 Mar;121(3):866-79. doi: 10.1172/JCI42928.

37.

Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden.

Connelly L, Barham W, Onishko HM, Sherrill T, Chodosh LA, Blackwell TS, Yull FE.

Oncogene. 2011 Mar 24;30(12):1402-12. doi: 10.1038/onc.2010.521. Epub 2010 Nov 15.

38.

P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis.

McHenry PR, Sears JC, Herrick MP, Chang P, Heckman-Stoddard BM, Rybarczyk M, Chodosh LA, Gunther EJ, Hilsenbeck SG, Rosen JM, Vargo-Gogola T.

Breast Cancer Res. 2010;12(5):R73. doi: 10.1186/bcr2643. Epub 2010 Sep 22.

39.

Akt is required for Stat5 activation and mammary differentiation.

Chen CC, Boxer RB, Stairs DB, Portocarrero CP, Horton RH, Alvarez JV, Birnbaum MJ, Chodosh LA.

Breast Cancer Res. 2010;12(5):R72. doi: 10.1186/bcr2640. Epub 2010 Sep 17.

40.

HIF-2alpha deletion promotes Kras-driven lung tumor development.

Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, Jacks T, Chodosh LA, Kissil JL, Simon MC, Keith B.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14182-7. doi: 10.1073/pnas.1001296107. Epub 2010 Jul 21.

41.

The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2.

Zeng X, Shaikh FY, Harrison MK, Adon AM, Trimboli AJ, Carroll KA, Sharma N, Timmers C, Chodosh LA, Leone G, Saavedra HI.

Oncogene. 2010 Sep 9;29(36):5103-12. doi: 10.1038/onc.2010.253. Epub 2010 Jun 28.

42.

Activation of nuclear factor kappa B in mammary epithelium promotes milk loss during mammary development and infection.

Connelly L, Barham W, Pigg R, Saint-Jean L, Sherrill T, Cheng DS, Chodosh LA, Blackwell TS, Yull FE.

J Cell Physiol. 2010 Jan;222(1):73-81. doi: 10.1002/jcp.21922.

43.

mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging.

Castilho RM, Squarize CH, Chodosh LA, Williams BO, Gutkind JS.

Cell Stem Cell. 2009 Sep 4;5(3):279-89. doi: 10.1016/j.stem.2009.06.017.

44.

Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition.

McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL.

J Clin Invest. 2009 Sep;119(9):2663-77. doi: 10.1172/JCI37691. Epub 2009 Aug 24.

45.

The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis.

Wertheim GB, Yang TW, Pan TC, Ramne A, Liu Z, Gardner HP, Dugan KD, Kristel P, Kreike B, van de Vijver MJ, Cardiff RD, Reynolds C, Chodosh LA.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15855-60. doi: 10.1073/pnas.0906993106. Epub 2009 Aug 28.

46.

ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.

Muraoka-Cook RS, Sandahl MA, Strunk KE, Miraglia LC, Husted C, Hunter DM, Elenius K, Chodosh LA, Earp HS 3rd.

Mol Cell Biol. 2009 Sep;29(18):4935-48. doi: 10.1128/MCB.01705-08. Epub 2009 Jul 13.

47.

Abnormal mammary gland development in MMTV-CBLC transgenic mouse.

Fiore F, Estebe B, Gibier P, Orsoni JC, Courbard JR, Chodosh LA, Birnbaum D, Delapeyrière O.

In Vivo. 2009 Mar-Apr;23(2):225-8.

48.

Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors.

Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PH.

Cancer Prev Res (Phila). 2008 Jun;1(1):45-55. doi: 10.1158/1940-6207.CAPR-08-0034. Epub 2008 Mar 31.

49.

Singular value decomposition-based regression identifies activation of endogenous signaling pathways in vivo.

Liu Z, Wang M, Alvarez JV, Bonney ME, Chen CC, D'Cruz C, Pan TC, Tadesse MG, Chodosh LA.

Genome Biol. 2008;9(12):R180. doi: 10.1186/gb-2008-9-12-r180. Epub 2008 Dec 18.

50.

Purification of DNA-binding proteins using biotin/streptavidin affinity systems.

Chodosh LA, Buratowski S.

Curr Protoc Protein Sci. 2001 May;Chapter 9:Unit 9.7. doi: 10.1002/0471140864.ps0907s12.

PMID:
18429216

Supplemental Content

Loading ...
Support Center